Opinion|Videos|February 14, 2025
A case of a mother experiencing PPD while on low-dose SSRI
Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.
Advertisement
Episodes in this series
Advertisement
Related to this article
Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5